Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?

摘要

DCCT , UKPDS and Kumamoto studies clearly indicate that good glycaemic control can reduce the risk of nephropathy in subjects with both type 1 and type 2 diabetes. Furthermore, the recent ADVANCE trial confirmed that much tighter glycaemic control (mean HbA1c = 6.5%) is beneficial for nephropathy in subjects with type 2 diabetes . In order to achieve tight glycaemic control, we would like to try to describe which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how, in this comment